Allegra (Fexofenadine) and Azelastine Are NOT Indicated for Treating Respiratory Infections
Yes, Allegra is fexofenadine, but neither fexofenadine nor azelastine should be combined to "fight respiratory infections"—these are antihistamines indicated for allergic rhinitis, not antimicrobial agents for infections. 1, 2
Critical Distinction: Allergy vs. Infection
What These Medications Actually Treat
Fexofenadine (Allegra): A second-generation oral antihistamine approved for seasonal and perennial allergic rhinitis. It blocks histamine H1 receptors and is non-sedating at recommended doses 1
Azelastine: An intranasal antihistamine with H1-receptor antagonist activity, also approved for allergic rhinitis (both seasonal and perennial) and vasomotor rhinitis 1, 2
Neither medication has FDA approval or guideline support for treating respiratory infections like the common cold, influenza, or bacterial sinusitis.
The Evidence on Respiratory Infections
Limited Emerging Data (Not Standard Practice)
Recent research has explored azelastine's potential antiviral properties:
- A 2023 study showed in vitro antiviral activity against SARS-CoV-2, RSV, influenza, and other respiratory viruses 3
- A 2024 phase 2 trial demonstrated azelastine nasal spray reduced viral load in mild COVID-19 patients 4
- A 2025 trial showed azelastine reduced SARS-CoV-2 infection risk when used prophylactically 5
However, these are preliminary findings in experimental settings and do not represent established clinical practice or FDA-approved indications. 3, 5, 4
No Evidence for Fexofenadine in Infections
One case series combined naproxen with fexofenadine for common cold symptoms, but this was anecdotal and not a controlled trial 6. There is no robust evidence supporting fexofenadine for respiratory infections.
When Combination Therapy IS Appropriate
For Allergic Rhinitis (The Actual Indication)
The combination of oral antihistamine (like fexofenadine) with intranasal antihistamine (like azelastine) can be considered for allergic rhinitis:
Guideline recommendation: For patients with seasonal allergic rhinitis who remain symptomatic on fexofenadine alone, adding azelastine nasal spray significantly improves total nasal symptom scores 1, 7
Evidence: A study showed azelastine nasal spray improved symptoms in patients inadequately controlled on fexofenadine monotherapy 7
However: Intranasal corticosteroids remain the most effective monotherapy for moderate-to-severe allergic rhinitis 1, 8
Common Pitfalls to Avoid
Misdiagnosing infection as allergy: Patients with viral upper respiratory infections present with rhinorrhea and congestion, but typically have systemic symptoms (fever, myalgias, sore throat) and lack the itching/sneezing prominent in allergic rhinitis 9
Inappropriate antihistamine use: Antihistamines are "generally ineffective for nonallergic rhinitis" including viral infections 1
Delaying appropriate treatment: If a patient has a bacterial respiratory infection requiring antibiotics, using antihistamines alone delays necessary antimicrobial therapy
Sedation risk: While fexofenadine is non-sedating, azelastine causes somnolence in 11.5% of patients and bitter taste in 19.7% 1, 2
The Bottom Line
For respiratory infections: Neither fexofenadine nor azelastine are standard treatments. Supportive care, rest, hydration, and appropriate antimicrobials (if bacterial) remain the evidence-based approach.
For allergic rhinitis: The combination can be considered for inadequate symptom control, but intranasal corticosteroids should be first-line for moderate-to-severe disease 1, 8, 10.